GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Ken Fisher's Top Increases of the First Quarter

April 22, 2014 | About:
Monica Wolfe

Monica Wolfe

123 followers
CEO and CIO of Fisher Investments, Ken Fisher, had a pretty busy first quarter. Fisher purchased a total of 57 new stocks. His first quarter portfolio holds 541 stocks and is valued at over $44.34 billion. The following five stocks represent the five companies where Fisher made the largest increase in holdings.

KB Financial Group (KB)

The largest increase made by Ken Fisher (Trades, Portfolio) over the duration of the first quarter was in KB Financial where upped his stake 1643.66% by purchasing a total of 82,183 stocks. He bought these shares in the first quarter price range of $32.34 to $40.51, with an estimated average quarterly price range of $35.37 per share. Since his buy the price per share is down roughly -0.8%.

Fisher now holds on to 87,183 shares of the company’s stock, representing a minor 0.0069% of his total portfolio as well as 0.02% of the company’s shares outstanding.

Ken Fisher (Trades, Portfolio)’s historical holding history:

1398197084754.png

KB Financial Group, and its subsidiaries, provides banking and related financial services to consumers and corporations in Korea and in selected international markets.

KB Financial Group’s historical revenue and net income:

1398199146416.png

The analysis on KB Financial Group reports that the company has enough cash to cover all of its debt, it has shown predictable revenue and earnings growth, and its dividend yield is near a 10-year high.

The Peter Lynch Chart suggests that the company is currently undervalued:

1398199395676.png

KB Financial has a market cap of $13.56 billion. Its shares are currently trading at around $35.10 with a P/E ratio of 13.00, a P/S ratio of 1.70 and a P/B ratio of 0.60. KB Financial Group had an annual average earnings growth of 7.20% over the past five years.

Celgene Corp (CELG)

The guru’s second largest increase of the first quarter was in Celgene Corp. where he upped his stake 1591.8% by purchasing 35,115 shares of the company’s stock. Fisher bought these shares in the quarterly price range of $139.29 to $171.94, with an estimated average quarterly price of $158.60 per share. Since then the price per share has dropped -7.8%.

Fisher now holds on to 37,321 shares of Celgene stock, representing 0.012% of his total portfolio as well as 0.01% of the company’s shares outstanding. This buy is also the first quarter not representing a sell for the guru since the second quarter of 2012.

Ken Fisher (Trades, Portfolio)’s historical holding history:

1398197431145.png

Celgene is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Celgene’s historical revenue and earnings growth:

1398199984568.png

The analysis on Celgene reports that the company has a high Piotroski F-Score, it has a poor stock buyback track record and over the past three years the company has issued $3.5 billion of debt.

The Peter Lynch Chart suggests that the company is currently overvalued:

1398200170524.png

Celgene has a market cap of $59.54 billion. Its shares are currently trading at around $146.64 with a P/E ratio of 43.60, a P/S ratio of 9.80 and a P/B ratio of 10.70. The company had an annual average earnings growth of 22.10% over the past five years.

Rolls-Royce Holdings (RYCEY)

Fisher’s third largest increase of the quarter was in Rolls-Royce where he upped his stake 845.5% by purchasing 651,613 shares of the company’s stock. He bought these in the quarterly price range of $80.00 to $106.03, with an estimated average price of $93.38. Since then the price per share has dropped approximately -3.7%.

Fisher now owns 725,970 shares of Rolls-Royce Holdings, representing 0.15% of his total assets managed as well as 0.19% of the company’s shares outstanding.

Fisher’s historical holding history:

1398197677883.png”

Rolls-Royce Holdings PLC manufactures aero, marine and industrial gas turbines for civil and military aircraft. The Group designs, constructs,supplies and installs power generation systems, transmission and distribution systems, and equipment for the marine propulsion, oil and gas pumping, and defense markets.

Rolls-Royce’s historical revenue and net income:

1398200432971.png

The analysis on Rolls-Royce reports that the company has issued GBP751 million in debt over the past year, it has a poor stock buyback record and its asset growth is faster than its revenue growth. The analysis also notes that the company’s operating margin is expanding, its dividend yield is near a 10-year high and its P/B and P/S ratios are trading near historical lows.

The Peter Lynch Chart suggests that the company is currently slightly undervalued:

1398200476058.png

Rolls-Royce has a market cap of $33.8 billion. Its shares are currently trading at around $89.87 with a P/E ratio of 14.70, a P/S ratio of 1.30 and a P/B ratio of 3.10. The company had an annual average earnings growth of 5.70% over the past five years.

Biogen Idec (BIIB)

Over the past quarter Fisher upped his holdings in Biogen Idec 796.27% by purchasing a total of 16,228 shares of the company’s stock. He bought these shares in the price range of $273.52 to $351.94, with an estimated first quarter average price of $316.78 per share. Since then the price per share is down approximately -3%.

Fisher now holds on to 18,266 shares of the company’s stock, representing 0.013% of his total portfolio and 0.01% of the company’s shares outstanding. This is the largest buy Ken Fisher (Trades, Portfolio) has made into Biogen.

Fisher’s historical holding history:

1398198360562.png”

Biogen is a global biotechnology company that discovers, develops, manufactures and markets therapies for the treatment of multiple sclerosis (MS) and other autoimmune disorders, neurodegenerative diseases and hemophilia.

Biogen’s historical revenue and net income:

1398200750092.png

The analysis on Biogen reports that the company holds enough cash to cover all of its debt, its operating margin is expanding and its Piotroski F-Score is high.

The Peter Lynch Chart suggests that the company is currently overvalued:

1398200776468.png

Biogen has a market cap of $72.38 billion. Its shares are currently trading at around $306.20 with a P/E ratio of 39.10 and a P/S ratio of 10.60. The company had an annual average earnings growth of 25.70% over the past ten years.

China Mobile (CHL)

Over the past quarter Fisher upped his holdings in China Mobile 787.3% by purchasing 141,879 shares of the company’s stock. He bought these shares in the quarterly price range of $41.55 to $52.29, with an estimated average quarterly price of $47.50. Since then the price per share has dropped -2.6%.

Fisher now owns 159,900 shares of China Mobile stock, representing 0.016% of his total assets managed and 0.00% of the company’s shares outstanding.

Fisher’s historical holding history:

1398198901901.png

China Mobile provides a range of mobile telecommunications services in all 31 provinces, autonomous regions and directly-administered municipalities in Mainland China as well as in Hong Kong. It offers mobile telecommunications services mainly using the Global System for Mobile Communications, or GSM, standard.

China Mobile’s historical revenue and net income:

1398200954676.png

The Peter Lynch Chart suggests that the company is currently undervalued:

1398200982051.png

China Mobile has a market cap of $186.38 billion. Its shares are currently trading at around $46.36 with a P/E ratio of 8.90 and a P/S ratio of 2.00.

Check out Fisher’s complete first quarter portfolio here.

Try a free 7-day premium membership trial here.


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK